When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent ...

Kerros stock plummeted more than 70% premarket Thursday and Truist Securities analysts predict it will remain under pressure ...

Candel’s trial was conducted under the FDA’s Special Protocol Assessment program, meaning that its data could be used as a ...

Pourhassan and Kazempour are awaiting sentencing but could face up to 20 years in prison for each count of securities and ...

Lago, leaders at Pfizer and Eli Lilly have publicly stated that they intend to collaborate with the incoming administration ...

Learn how to leverage your end-of-year downtime to document achievements, update your professional presence and prepare for a ...

On election day, Tuesday, November 5, Americans will choose between former President Donald Trump and current Vice President ...

The EPIC Act has been proposed with bipartisan and industry support to give small molecule drugs the same protection against ...

The discontinuation caps off a turbulent development path for izokibep, which in September 2023 produced disappointing ...

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech ...

Around 25 companies have gone public this year, most of them in the early months. Most have tumbled from their original offer ...